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ABSTRACT
TRH-like peptides have been identified that differ from TRH (pGlu-
His-ProNH2) in the middle aminoacid. We have estimated TRH-like
immunoreactivity (TRH-LI) in human serum and urine by RIA with
TRH-specific antiserum 8880 or with antiserum 4319, which binds
most peptides with the structure pGlu-X-ProNH2. TRH was unde-
tectable in serum (,25 pg/mL), but TRH-LI was detected with anti-
serum 4319 in serum of 27 normal subjects, 21 control patients, and
12 patients with carcinoid tumors (range 17–45, 5–79, and 18–16,600
pg/mL, respectively). Because serum was kept for at least 2 h at room
temperature, which causes degradation of TRH, pGlu-Phe-ProNH2,
and pGlu-Tyr-ProNH2, serum TRH-LI is not caused by these peptides.
On high-performance liquid chromatography, serum TRH-LI coe-
luted with pGlu-Glu-ProNH2 (,EEP-NH2), a peptide produced in,
among others, the prostate. Urine of normals and control patients also
contained TRH-LI (range 1.14–4.97 and 0.24–5.51 ng/mL, respec-
tively), with similar levels in males and females. TRH represented
only 2% of urinary TRH-LI, and anion-exchange chromatography and
high-performance liquid chromatography revealed that most TRH-LI
in urine was ,EEP-NH2. In patients with carcinoid tumors, increased
urinary TRH-LI levels were noted (range 1.35–962.4 ng/mL). Urinary
TRH-LI correlated positively with urinary creatinine, and the urinary
clearance rate of TRH-LI was similar to the glomerular filtration rate.
In addition, serum TRH-LI was increased in 17 hemodialysis patients
(43–373 pg/mL). This suggests that serum ,EEP-NH2 is cleared by
glomerular filtration with little tubular resorption. The possible role
of the prostate as a source of urinary TRH-LI was evaluated in 11 men
with prostate cancer, showing a 25% decrease in urinary TRH-LI
excretion after prostatectomy (0.19 6 0.02 vs. 0.15 6 0.01 ng/mmol
creatinine, mean 6 SEM). However, TRH-LI was similar in sponta-
neously voided urine and in urine obtained through a nephrostomy
cannula from 16 patients with unilateral urinary tract obstruction
(0.15 6 0.01 vs. 0.14 6 0.01 ng/mmol creatinine). These data indicate
that: 1) TRH-LI in human serum represents largely ,EEP-NH2,
which is cleared by renal excretion; 2) part of urinary ,EEP-NH2 is
derived from prostatic secretion into the blood and not directly into
urine; and 3) urinary ,EEP-NH2 can be used as marker for carcinoid
tumors. (J Clin Endocrinol Metab 82: 3068–3073, 1997)
EARLY STUDIES concerning the presence of extrahypo-thalamic TRH (,EHP-NH2)1 have indicated that im-
munoreactive TRH is present in peripheral tissues, blood,
and urine (for reviews, see Refs. 1 and 2). Subsequent studies
revealed the presence of TRH-like immunoreactivity (TRH-
LI) distinct from authentic TRH in, among others, pituitary,
male reproductive system, and semen (3–10) and indicated
that TRH-LI in blood and urine is probably not caused by
TRH (11, 12). Recently, naturally occurring tripeptides have
been found that share the N- and C-terminal aminoacids with
TRH but differ in the middle aminoacid (for reviews, see
Refs. 1, 13) and cross-react, to varying extents, with antisera
raised against TRH (6, 14–16). In human prostate and sem-
inal fluid ,EQP-NH2 and ,EFP-NH2 have been identified
(17–19), whereas ,EYP-NH2 has been found in alfalfa (20).
Another TRH-like peptide is ,EEP-NH2, which has been
detected in pituitary, prostate, and seminal fluid of various
mammalian species (including man, rat, and rabbit) (7, 8,
21–25). Although knowledge of the biological function of this
peptide is limited, ,EEP-NH2 has been found to increase the
capacitation and fertilization capacity of mouse and human
sperm (26, 27) and is therefore also called: fertilization pro-
moting peptide (13). Moreover, ,EEP-NH2 increases the mo-
tility of sperm from certain infertile men (19) and inhibits the
acrosome reaction of mouse sperm (28). In rats, ,EEP-NH2
has effects on pituitary GH secretion (23, 29), adrenal corti-
costerone secretion (30), and behavior (31). Though high
levels of ,EEP-NH2 can antagonize effects of TRH (23, 32),
the biological activity of ,EEP-NH2 is probably not exerted
via the TRH receptor (13, 32, 33).
Recently we reported on the presence of ,EEP-NH2 in a
human neuroblastoma cell line (34) and in serum of patients
with metastatic carcinoid tumors (16). In a preliminary study,
we observed that serum and urine of normal subjects also
contained TRH-LI. Because blood lacks pyroglutamylamin-
opeptidase I, a peptidase with broad specificity (25, 35), but
contains pyroglutamylaminopeptidase II, an enzyme with a
narrow substrate specificity that degrades TRH but not
,EEP-NH2 (25, 36), we hypothesized that TRH-LI in serum
and urine was ,EEP-NH2. In the present paper, we provide
evidence that indeed most TRH-LI in serum and urine rep-
resents ,EEP-NH2. In addition, we studied the possibility
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that urinary TRH-LI is derived from prostatic secretion and
may be used as a marker for carcinoid tumors.
Subjects and Methods
Subjects
The studies were done according to rules of the hospital medical
ethics committee. Normal healthy subjects [17 women aged 25–46 (me-
dian 28) yr, 10 men aged 27–57 (median 39) yr], patients with metastatic
carcinoid tumors [3 women aged 58–65 (median 62) yr, 9 men aged
30–70 (median 64) yr], control patients [14 women aged 20–76 (median
50) yr, 7 men aged 19–71 (median 54) yr], anuric patients undergoing
regular hemodialysis [7 women aged 27–73 (median 44) yr, 10 men aged
43–80 (median 47) yr], patients with short-lasting unilateral urinary tract
obstruction temporarily treated by unilateral nephrostomy [5 women
aged 41–76 (median 47) yr, 11 men aged 22–70 (median 47) yr], and
patients with prostate cancer [11 men aged 52–65 (median 61) yr] par-
ticipated in this study.
No drugs were used by the healthy normal subjects, except for con-
traceptives (9 of the 17 females), and none of them had a history of renal
disease. Ten of the 12 patients with carcinoid tumors were treated with
SRIH analog octreotide. The group of control (i.e. noncarcinoid) patients
consisted of 5 patients with disorders of lipid metabolism (most of them
were on lipid-lowering drugs), 5 patients with Cushing’s syndrome (2
patients with an adrenocortical tumor and 3 patients with untreated
Cushing’s disease), 3 patients with primary hyperparathyroidism, 2
patients with gonadotropin-secreting or clinically nonfunctioning pitu-
itary tumors, 2 patients with neurinomas/neurofibromas, 2 subjects who
underwent a routine check-up, 1 patient with colonic cancer, and 1
patient with untreated active acromegaly. None of these patients was
known to have renal disease or been treated with medications affecting
renal function. When appropriate, hypopituitarism in patients with pi-
tuitary tumors was treated by replacement therapy. None of the patients
with primary hyperparathyroidism or pituitary tumors was known with
the multiple endocrine neoplasia-I syndrome.
Collection of serum and urine
Basal, nonfasting blood samples were drawn from a peripheral vein.
Blood was taken from the anuric patients before hemodialysis. After
centrifugation, serum was kept for at least 2 h at room temperature to
ensure enzymatic TRH degradation. The normal subjects delivered a
morning urine sample, whereas 24-h urine was collected from control
and carcinoid patients. From these persons, urine was collected on the
same day as blood was sampled. In patients with obstructive uropathy,
24-h urine was collected from the obstructed kidney through a nephros-
tomy cannula and by spontaneous micturition. From patients with pros-
tate cancer, 24-h urine was collected the day before prostatectomy and
again 3–7 (median 5) days later. Serum and urine were kept at 220 C
before the measurements.
Serum degradation of TRH-LI
Serum degradation of ,EHP-NH2 (TRH), ,EDP-NH2, ,EEP-NH2,
,EQP-NH2, ,EFP-NH2, and ,EYP-NH2 was tested by adding 10 ng
peptide to 5 mL normal human serum kept at room temperature. At
several time intervals, 0.2-mL aliquots were removed and mixed with 1
mL methanol to stop further peptide degradation. After centrifugation,
supernatants were removed, dried under a stream of nitrogen at room
temperature, dissolved in 1 mL phosphate buffer (pH 7.4), and stored
at 220 C until analysis of TRH-LI. After removal of aliquots for RIA
measurements, the rest of the serum was extracted with methanol to
determine the nature of the residual TRH-LI by isocratic reverse-phase
high-performance liquid chromatography (HPLC).
Chromatography
Urine. To 1 vol urine were added 2 vol ethanol. The mixture was kept
at 4 C for 1 h, and after centrifugation, the supernatant was isolated and
dried under a stream of nitrogen. The residue was reconstituted in 2 mL
0.05 m Tris-HCl (pH 7.6) containing 0.02% (wt/vol) sodium azide, and
7500 cpm [125I],EHPG were added as calibration marker. The nature of
the TRH-LI in the extracts was analyzed by QAE-Sephadex A-25 (Phar-
macia, Uppsala, Sweden), anion-exchange chromatography, and iso-
cratic reverse-phase HPLC as previously reported (16, 34). TRH-LI in the
fractions was assayed by RIA using antiserum 4319. Before each session,
the HPLC column was calibrated with 2000 cpm [3H],EHP-NH2 and
2000 cpm [3H],EEP-NH2. Blank runs were performed between sample
analyses to prevent contamination. Elution positions of synthetic TRH-
like peptides were determined in separate sessions for both anion-
exchange chromatography and HPLC. Recovery of TRH-LI after the
chromatographic procedures was at least 85%.
Serum. To 5 mL serum was added 7.5 mL 1% (wt/vol) trifluoracetic acid,
and the mixture was applied to a Sep-Pak C18 cartridge (Waters, Mil-
ford, MA). After washing with 1% trifluoracetic acid and water, TRH-LI
was eluted with methanol. The solvent was evaporated, the residue was
taken up in HPLC buffer, filtered through a Centricon-10 concentrator
(Amicon, Capelle a/d IJssel, The Netherlands), and analyzed by HPLC
as described above.
Assays
Levels of TRH-LI were determined by RIA using antiserum 4319 or
8880 (14, 16). Although both antisera were raised against the same
antigen, antiserum 8880 specifically recognizes TRH and hardly cross-
reacts with ,EEP-NH2, whereas antiserum 4319 detects most peptides
with the general structure ,EXP-NH2 (14–16). Antisera 4319 and 8880
were used at a final dilution of 1:20,000 and 1:50,000, respectively, in the
RIAs employing [125I]TRH as tracer, unlabeled TRH as standard, and
0.1–0.2 mL serum or 0.1 mL diluted urine extract as sample. Detection
limits for assays with antisera 4319 and 8880 are 5–10 and 15–25 pg
TRH/mL, respectively, and intra- and interassay variation varied be-
tween 8 and 14%. Regardless of the antiserum used, TRH-LI levels are
presented as TRH equivalents. Because urea may interfere with the
measurement of TRH-LI (11), the effect of urea was tested in the RIA;
even high urea levels (165 mmol/L) did not displace [125I]TRH from
antisera 4319 and 8880. Creatinine and prostate specific antigen (PSA)
were measured by routine laboratory methods.
Chemicals
,EHP-NH2 and ,EEP-NH2 were purchased from Bissendorf
(Hannover, Germany); ,EFP-NH2, ,EQP-NH2 and ,EHPG from Pen-
insula (Belmont, CA); and ,EDP-NH2 and ,EYP-NH2 from UCB (Brus-
sels, Belgium). [3H]TRH (43 Ci/mmol) was obtained from Amersham
(Aylesbury, UK), and [3H],EEP-NH2 (30 Ci/mmol) was a gift of Dr.
S. M. Cockle (Reading, UK). [125I]TRH and [125I],EHPG were prepared
and purified by HPLC as previously described (37). All other chemicals
were of analytical grade.
Statistical analyses
The results are presented as means 6 sem or range and median.
Statistical tests included Mann-Whitney U test, Wilcoxon matched-pairs
signed-ranks test, and linear regression analysis. P # 0.05 was consid-
ered significant.
Results
Serum and urinary creatinine levels
Serum creatinine was within normal limits (60–110
mmol/L) in most subjects, with the exception of one carcinoid
patient (140 mmol/L); all hemodialysis patients (range 320-
1543 mmol/L); and 2 patients with unilateral urinary tract
obstruction (134 and 182 mmol/L). Creatinine was lower in
nephrostomy urine (4950 6 520 mmol/L) than in spontane-
ously voided urine (6910 6 1010 mmol/L).
TRH-LI in serum and urine of normals, control patients,
and patients with metastatic carcinoids
TRH-LI was undetectable by RIA with TRH-specific an-
tiserum 8880 in sera of normal subjects, control patients, and
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patients with metastatic carcinoid tumors (,25 pg/mL), but
TRH-LI was detected in these sera using nonspecific anti-
serum 4319 (Table 1). With values between 18 and 16600
pg/mL, mean serum TRH-LI in carcinoid patients was sig-
nificantly higher than in normal subjects and control patients
(Fig. 1, Table 1). Substantial amounts of TRH-LI were de-
tected by RIA with antiserum 4319 in morning urine of nor-
mal subjects (Table 1), whereas only low levels were found
by RIA with the TRH-specific antiserum 8880 (women 29 6
3, men 39 6 6 pg/mL). Serial dilutions of urine produced a
dose-response curve parallel to those of ,EEP-NH2 and TRH
in the RIA with antiserum 4319 (Fig. 2), and ,EEP-NH2
added to urine was recovered quantitatively (data not
shown). Although TRH-LI levels in 24-h urine of control
patients were, in general, lower than values in morning urine
of normal subjects, this difference disappeared when urinary
TRH-LI was corrected for urinary creatinine content (Table
1). Urinary TRH-LI was not different between males and
females (Table 1). Levels of TRH-LI in 24-h urine of patients
with metastatic carcinoid tumors varied between 1.35 and
962.4 ng/mL, which is significantly higher than values in
control male patients (Fig. 1, Table 1).
In normal subjects and control patients, no significant cor-
relation was found between serum and urine levels of
TRH-LI (Fig. 1; r 5 0.27, P 5 0.07), even after correction of
the latter for the urinary creatinine content (r 5 0.07). Urinary
TRH-LI, however, correlated significantly with urinary cre-
atinine (r 5 0.76, P , 0.01). In patients with metastatic car-
cinoid tumors, serum TRH-LI correlated significantly with
urinary TRH-LI (Fig. 1; r 5 0.95, P , 0.01).
Based on the data concerning urine production and levels
of TRH-LI in serum and urine of the 21 control patients, the
urinary clearance rate of serum TRH-LI was calculated from
the formula: [TRH-LI]urine 3 urinary production rate 4
[TRH-LI]serum, yielding a value of 117 6 21 mL/min.
Serum degradation of TRH-LI
Disappearance of TRH-like peptides was tested in human
serum kept at room temperature (Fig. 3). No degradation of
,EDP-NH2, ,EQP-NH2, and ,EEP-NH2 was observed, and
HPLC analysis showed that these peptides remained intact
(data not shown). On the other hand, ,EHP-NH2 (TRH),
,EFP-NH2, and ,EYP-NH2 were degraded rapidly with
half-lives of 19, 31, and 16 min, respectively.
Chromatography of TRH-LI in serum and urine
The nature of TRH-LI in serum of normal subjects was
studied by HPLC, and most TRH-LI was found to coelute
with ,EEP-NH2 (data not shown). Ethanol-extracted urine
from normal subjects was examined by anion-exchange chro-
matography and HPLC, and typical results are shown in Fig.
4. Most urinary TRH-LI was retained on the QAE-Sephadex
A-25 anion-exchange column and, thus, was clearly sepa-
rated from authentic TRH, as well as basic and neutral TRH-
LI, which are not retained on this column. Further analysis
by HPLC revealed that urinary TRH-LI coeluted with
,EEP-NH2.
TRH-LI in serum of anuric patients
Serum TRH-LI measured by RIA with antiserum 4319 in
17 anuric patients was significantly higher (127 6 18 pg/mL,
P , 0.01) than that in control patients (18 6 4 pg/mL). No
difference in serum TRH-LI was observed between female
and male hemodialysis patients (110 6 20 and 138 6 29
pg/mL, respectively). HPLC analysis of sera from 2 of these
patients indicated that TRH-LI coeluted quantitatively with
,EEP-NH2 (data not shown). Serum TRH-LI in these pa-
tients correlated significantly with serum creatinine levels
(r 5 0.52, P , 0.025).
TRH-LI in urine of patients with unilateral urinary tract
obstruction
TRH-LI was estimated by RIA using antiserum 4319 in
urine from patients with unilateral urinary tract obstruction.
TRH-LI levels in urine sampled from the nephrostomy can-
nula were lower than in spontaneously voided urine, but this
difference disappeared when TRH-LI values were corrected
for the urinary creatinine content (Table 2). No significant
difference existed between female and male patients regard-
ing TRH-LI in nephrostomy cannula urine (0.13 6 0.03 and
0.15 6 0.01 ng/mmol creatinine, respectively) or spontane-
ously voided urine (0.15 6 0.01 and 0.14 6 0.03 ng/mmol
creatinine, respectively). Urinary TRH-LI in these patients
TABLE 1. Serum TRH-LI levels, and urinary TRH-LI and creatinine levels (means 6 SEM) in normal subjects, control patients, and
patients with metastatic carcinoid tumors
Serum TRH-LI
(pg/ml)
Urine TRH-LI
(ng/mL)
Urine
Creatinine
(mmol/mL)
Urine
TRH-LI/creatinine
(ng/mmol)
Normal subjects
Women (17) 26 6 2 2.28 6 0.17 13.2 6 1.4 0.18 6 0.01
Men (10) 26 6 1 2.42 6 0.38 13.8 6 2.2 0.20 6 0.02
Control patients
Women (14) 16 6 3 1.67 6 0.09a 10.4 6 2.0a 0.17 6 0.02
Men (7) 22 6 10 1.64 6 0.25 9.2 6 1.7 0.19 6 0.03
Carcinoid patients
Women (3) 117 6 39b 7.33 6 4.10 5.4 6 0.9a 1.50 6 0.83
Men (9) 2345 6 1828ab 174.8 6 114.4ab 8.7 6 1.6a 22.95 6 16.38ab
Morning urine was collected from the normal subjects, whereas 24-h urine was collected from the patients. TRH-LI was estimated by RIA
with the nonspecific antiserum 4319. Number of individuals is between parentheses.
a P , 0.01 compared with normal subjects.
b P , 0.01 compared with control patients.
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correlated significantly with urinary creatinine (r 5 0.93, P ,
0.01).
Serum PSA and urinary TRH-LI in men before and after
prostatectomy
Prostatectomy reduced serum PSA from 9.7 6 2.2 to 0.8 6 0.3
mg/L (P , 0.01, normal ,10 mg/L). Levels of TRH-LI in urine,
as estimated by RIA using antiserum 4319, were higher before
than after prostatectomy (1.7 6 0.3 vs 1.0 6 0.1 ng/mL; P ,
0.02), even after correction for urinary creatinine content (0.19 6
0.02 and 0.15 6 0.01 ng/mmol creatinine, respectively; P , 0.02).
Discussion
We have investigated the presence and nature of TRH-LI
in human serum and urine. Our two antisera, of which an-
tiserum 8880 is TRH-specific (14–16), enabled us to distin-
guish between authentic TRH and TRH-like peptides. No
authentic TRH could be detected in serum by RIA with
TRH-specific antiserum 8880, but TRH-LI was detected with
the nonspecific antiserum 4319. It should be stressed, how-
ever, that serum was kept for at least 2 h at room temperature
to ensure TRH degradation. In blood collected directly into
methanol or ethanol to block enzymatic degradation of TRH,
undetectable or barely detectable concentrations of authentic
TRH have been reported (11, 38). Because ,EFP-NH2 and
,EYP-NH2 also are rapidly degraded in serum, these pep-
tides also are unlikely to contribute to serum TRH-LI. On the
other hand, ,EDP-NH2, ,EQP-NH2, and ,EEP-NH2 are not
degraded and thus may contribute to serum TRH-LI. HPLC
analysis revealed that most TRH-LI in serum of normal sub-
jects represents ,EEP-NH2. Recently, ,EEP-NH2 also has
been identified in serum of elderly men (39) and in patients
with metastatic carcinoid tumors (16).
In urine of healthy subjects, significant amounts of TRH-LI
were measured by RIA using antiserum 4319. Only ;2% of
urinary TRH-LI was accounted for by authentic TRH, which
is in agreement with Suhonen-Malm (38), who reported that
urinary TRH varied between 2 and 12 pg/mL. Further anal-
ysis revealed that most urinary TRH-LI was retained on the
anion-exchange column and coeluted with synthetic ,EEP-
NH2 on HPLC. Thus, substantial amounts of ,EEP-NH2 are
present in human urine.
The presence of ,EEP-NH2 in serum and urine suggests
that ,EEP-NH2 is cleared from blood by renal excretion. This
FIG. 1. Relation between serum and
urine levels of TRH-LI in 27 healthy
normal subjects (closed circles, left pan-
el), 21 control patients (open circles, left
panel), and 12 patients with metastatic
carcinoid tumors (right panel). TRH-LI
was determined with the nonspecific
antiserum 4319. No authentic TRH
could be detected in these serum sam-
ples with the TRH-specific antiserum
8880.
FIG. 2. Inhibition of [125I]TRH binding to antiserum 4319 by increasing
concentrations of TRH or ,EEP-NH2, or increasing volumes of urine.
FIG. 3. Degradation of TRH and TRH-like peptides in human serum
kept at room temperature. Ten nanograms of peptide was added to 5
mL serum and aliquots of 0.2 mL were removed at various time
intervals and mixed with 1 mL methanol. The extracts were assayed
for TRH-LI using the nonspecific antiserum 4319.
,EEP-NH2 IN URINE 3071
 at Medical Library Erasmus MC on December 13, 2006 jcem.endojournals.orgDownloaded from 
is supported by our observations that serum TRH-LI is in-
creased in anuric patients on hemodialysis and that a good
correlation exists between TRH-LI and creatinine in urine.
For control (i.e. noncarcinoid) patients, the urinary clearance
rate of TRH-LI amounted to 117 6 21 mL/min, which is
similar to the normal glomerular filtration rate (;125 mL/
min). Thus, ,EEP-NH2 seems to be cleared from blood by
glomular filtration with little tubular reabsorption. This is in
contrast to most peptides, which are reabsorbed or undergo
significant renal metabolism (40, 41). We have recently found
also that after iv injection of ,EEP-NH2 in rats, the peptide
is recovered quantitatively in the urine (42). Thus, it seems
that urinary ,EEP-NH2 can be used as an indicator of the
total amount of ,EEP-NH2 released into the blood.
The similarity of serum and urinary TRH-LI in men and
women suggests minor contributions of prostatic ,EEP-NH2
secretion. This conclusion is corroborated by the effect of pros-
tatectomy in patients with prostate cancer. Although urinary
TRH-LI was reduced 5 days after prostatectomy, this reduction
amounted to only 25%. However, it should be mentioned that
TRH-LI is virtually absent from prostate cancer tissue (43).
Therefore, the effect of prostatectomy in patients with prostate
cancer may not be representative of the contribution of the
prostate to serum and urinary TRH-LI levels in healthy males.
A major contribution of prostatic ,EEP-NH2 secretion directly
into the urinary tract is also unlikely because patients with
unilateral nephrostomy had similar TRH-LI levels per mmol
creatinine in urine collected from the renal pelvis, which is not
contaminated by prostatic secretory products, and in sponta-
neously voided urine. Together, our results suggest that a major
source of ,EEP-NH2, other than the prostate, is present in
humans.
As for an alternative source of ,EEP-NH2, this peptide is
present in the pituitary of various species, including rat, rabbit,
pig, and domestic fowl (see Ref. 13 for review). However, anal-
ysis of TRH-LI in serum obtained by bilateral inferior petrosal
sinus sampling in humans suggests that hypophyseal ,EEP-
NH2 is a negligible source of serum TRH-LI
2. In analogy with
the presence of ,EYP-NH2 in alfalfa (20), serum and urinary
,EEP-NH2 may be derived from food. However, urinary
TRH-LI in normal subjects is not affected by fasting3, suggesting
a minor dietary intake of ,EEP-NH2. Also in rats, evidence has
been obtained that ,EEP-NH2 in serum and urine is not de-
rived from food (42). Thus, further research is needed to identify
the origin of ,EEP-NH2 in serum and urine.
No significant correlation was found between serum and
urinary TRH-LI in healthy subjects and in control patients.
Variable serum TRH-LI levels have been detected previously by
us (16) in control subjects (range 9–193 pg/mL, n 5 175), and
recent studies in our laboratory suggest an episodic variation in
serum TRH-LI in healthy women2. The latter phenomenon may
explain the lack of correlation between serum and urinary
TRH-LI in normal subjects and in control patients.
The finding that ,EEP-NH2 is excreted in urine has pos-
sible clinical implications. In healthy subjects, serum TRH-LI
is low, but increased levels have been found in 36 of 72
patients with carcinoid tumors (16, present study). In abso-
lute terms, however, serum levels remain rather low in many
of these patients. TRH-LI levels in urine are ;1003 higher
than in serum, and urinary TRH-LI correlates with serum
TRH-LI in carcinoid patients. Therefore, urinary TRH-LI may
be a more accurate and sensitive parameter for evaluation of
patients with carcinoid tumors than serum TRH-LI. In the
present study, serum TRH-LI was higher than the upper
normal limit (75 pg/mL; Ref. 16) in 8 of the 12 patients with
metastatic carcinoid tumors, whereas urinary TRH-LI was
higher than the upper normal limit (0.31 ng/mmol creatinine)
in 10 of the 12 patients. Urinary 5-hydroxyindoleacetic acid
excretion was elevated in 10 of the subjects, and the 2 patients
who did not have increased urinary 5-hydroxyindoleacetic
2 W. J. de Greef, W. W. de Herder, C. B. Lambalk, W. Klootwijk, E.
Sleddens-Linkels and T. J. Visser. The TRH-like peptide pyroglutamyl-
glutamyl-prolineamide in human serum is not secreted from the pitu-
itary gland. (Manuscript submitted for publication).
3 W. Klootwijk, E. J. Rolleman, G. Henneman, T. J. Visser and W. J.
de Greef, unpublished observations.
FIG. 4. Typical analysis of TRH-LI in ethanol-extracted urine from a
healthy subject by QAE-A25 Sephadex anion-exchange chromatog-
raphy (A) and isocratic reverse phase HPLC (B). Arrows indicate
elution positions of ,EHP-NH2 (TRH; 1), ,EDP-NH2 (2), ,EQP-NH2
(3), ,EEP-NH2 (4), and [
125I],EHPG (5). TRH-LI in the fractions was
determined by RIA with the nonspecific antiserum 4319.
TABLE 2. Levels of TRH-LI and creatinine (means 6 SEM) in
spontaneously voided urine and in urine collected from a
nephrostomy cannula in 17 patients with unilateral urine tract
obstruction
TRH-LI
(ng/mL)
Creatinine
(mmol/mL)
TRH-LI/creatinine
(ng/mmol)
Spontaneous 1.09 6 0.23 6.9 6 1.0 0.15 6 0.01
Nephrostomy
cannula
0.73 6 0.11a 5.0 6 0.5a 0.14 6 0.01
a P , 0.01 compared with spontaneously voided urine.
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acid excretion showed elevated urinary TRH-LI levels.
Therefore, urinary TRH-LI may be used to identify gastro-
intestinal carcinoids, a group of tumors with variable bio-
chemical, morphological, and biological characteristics (44).
In conclusion, we have demonstrated that most TRH-LI in
human blood is caused by ,EEP-NH2, which is cleared from
blood by renal excretion. The prostate is not a major source
of urinary TRH-LI. Finally, urinary ,EEP-NH2 may be used
as marker for carcinoid tumors.
Acknowledgments
We are indebted to our colleagues in the Dijkzigt Hospital Rotterdam,
Drs. T. van Gelder and I. C. van Riemsdijk (Department of Internal
Medicine I), N. Hoogerbrugge-van der Linden and H. A. P. Pols (De-
partment of Internal Medicine III), and C. H. H. Schoenmakers (Labo-
ratory for Clinical Chemistry) for their kind cooperation in these studies.
The authors thank the nursing staffs of the Departments of Urology,
Internal Medicine III, and Nephrology for the excellent patient care.
References
1. Ashworth RJ. 1994 Thyrotropin-releasing hormone (TRH)-related peptides.
Mol Cell Endocrinol. 101:C1–C3.
2. Iversen E. 1995 Thyrotropin releasing hormone. Occurrence and role outside
the central nervous system. Dan Med Bull. 42:257–268.
3. Pekary AE, Meyer NV, Vaillant C, Hershman JM. 1980 Thyrotropin-releasing
hormone and a homologous peptide in the male reproductive system. Biochem
Biophys Res Commun. 95:993–1000.
4. Pekary AE, Sharp B, Briggs J, Carlson HE, Hershman JM. 1983 High con-
centrations of p-Glu-His-Pro-NH2 (thyrotropin-releasing hormone) occur in
rat prostate. Peptides. 4:915–919.
5. Pekary AE, Hershman JM, Friedman S. 1983 Human semen contains thyro-
tropin-releasing hormone (TRH), a TRH-homologous peptide, and TRH-bind-
ing substances. J Androl. 4:399–407.
6. Pekary AE, Lukaski HC, Mena I, Smith SM, Bhasin S, Hershman JM. 1993
Testosterone increases TRH biosynthesis in epididymis but not heart of zinc-
deficient rats. Peptides. 14:315–324.
7. Cockle SM, Aitken A, Beg F, Smyth DG. 1989 A novel peptide, pyroglu-
tamylglutamylproline-amide, in the rat prostate complex, structurally related
to thyrotrophin-releasing hormone. J Biol Chem. 264:7788–7791.
8. Cockle SM, Aitken A, Beg F, Morrell J, Smyth DG. 1989 The TRH-related
peptide pyroglutamylglutamylprolineamide is present in human semen. FEBS
Lett. 252:113–117.
9. Fuse Y, Polk DH, Lam RW, Fisher DA. 1990 Distribution of thyrotropin-
releasing hormone (TRH) and precursor peptide (TRH-Gly) in adult rat tissues.
Endocrinology. 127:2501–2505.
10. Montagne J, Ladram A, Grouselle D, Nicolas P, Bulant M. 1996 Identification
and cellular localization of thyrotropin-releasing hormone-related peptides in
rat testis. Endocrinology. 137:185–191.
11. Iversen E. 1986 Thyrotropin-releasing hormone cannot be detected in plasma
from normal subjects. J Clin Endocrinol Metab. 63:516–519.
12. Vagenakis AG, Roti E, Mannix J, Braverman LE. 1975 Problems in the mea-
surement of urinary TRH. J Clin Endocrinol Metab. 41:801–804.
13. Cockle SM. 1995 Fertilization promoting peptide (FPP): a novel peptide,
structurally similar to thyrotropin-releasing hormone, with potent physiolog-
ical activity. J Endocrinol. 146:3–8.
14. Rondeel JMM, Klootwijk W, Linkels E, van Haasteren GAC, de Greef WJ,
Visser TJ. 1995 Regulation of the TRH-like peptide pyroglutamyl-glutamyl-
prolineamide in the rat anterior pituitary gland. J Endocrinol. 145:43–49.
15. Klootwijk W, Vaessen LMB, Bernard BF, Rondeel JMM, de Greef WJ, Visser
TJ. 1995 Production and characterization of monoclonal and polyclonal anti-
bodies against thyrotropin-releasing hormone. Hybridoma. 14:285–290.
16. Klootwijk W, de Herder WW, Kwekkeboom DJ, et al. 1996 High levels of the
thyrotropin-releasing hormone-like peptide pyroglutamyl-glutamyl-pro-
lineamide in patients with carcinoid tumors. J Clin Endocrinol Metab.
81:2816–2820.
17. Khan Z, Aitken A, del Rio-Garcia J, Smyth DG. 1992 Isolation and identi-
fication of two neutral thyrotropin releasing hormone-like peptides, pyroglu-
tamylphenylalanineproline amide and pyroglutamylglutamineproline amide,
from human seminal fluid. J Biol Chem. 267:7464–7469.
18. Gkonos PJ, Kwok CK, Block NL, Roos BA. 1994 Identification of the human
seminal TRH-like peptide pGlu-Phe-ProNH2 in normal human prostate. Pep-
tides. 15:1281–1283.
19. Linden H, del Rio Garcia J, Huber A, Kreil G, Smyth D. 1996 The TRH-like
peptides in rabbit testis are different from the TRH-like peptide in the prostate.
FEBS Lett. 379:11–14.
20. Lackey DB. 1992 Isolation and structural determination of a novel TRH-
like tripeptide, pyroGlu-Tyr-Pro amide, from alfalfa. J Biol Chem.
267:17508–17511.
21. Ashworth RJ, Visser TJ, Cockle SM. 1991 The TRH-like peptide pGlu-Glu-
ProNH2 is present in porcine pituitary but not in reproductive tissues. Biochem
Biophys Res Commun. 181:1557–1563.
22. Akinsanya KO, Ghatei MA, Bloom SR. 1995 Gonadal steroids regulate rat
anterior pituitary levels of TSH-releasing hormone- and pyroglutamyl-glu-
tamyl-proline amide-like immunoreactivity. Endocrinology. 136:734–740.
23. Rondeel JMM, Klootwijk W, Linkels E, et al. 1995 Further studies on the reg-
ulation, localization and function of the TRH-like peptide pyroglutamyl-glutamyl-
prolineamide in the rat anterior pituitary gland. J Endocrinol. 146:293–300.
24. Bilek R, Gkonos PJ, Tavianini MA, Smyth DG, Roos BA. 1992 The thyro-
tropin-releasing hormone (TRH)-like peptides in rat prostate are not formed
by expression of the TRH gene but are suppressed by thyroid hormone. J
Endocrinol. 132:177–184.
25. Cockle SM, Prater GV, Thetford CR, Hamilton C, Malone PR, Mundy AR.
1994 Peptides related to thyrotrophin-releasing hormone (TRH) in human
prostate and semen. Biochim Biophys Acta. 1227:60–66.
26. Green CM, Cockle SM, Watson PF, Fraser LR. 1994 Stimulating effect of pyro-
glutamylglutamylprolineamide, a prostatic TRH-related tripeptide, on mouse
sperm capacitation and fertilizing ability in vitro. Mol Reprod Dev. 38:215–221.
27. Green CM, Cockle SM, Watson PF, Fraser LR. 1996 Fertilization promoting
peptide, a tripeptide similar to thyrotrophin-releasing hormone, stimulates the
capacitation and fertilizing ability of human spermatozoa in vitro. Hum Re-
prod. 11:830–836.
28. Green CM, Cockle SM, Watson PF, Fraser LR. 1996 A possible mechanism of
action for fertilization promoting peptide, a TRH-related tripeptide that pro-
motes capacitation and fertilizing ability in mammalian spermatozoa. Mol
Reprod Dev. 45:244–252.
29. Ashworth RJ, Ham J, Cockle SM. 1994 The effects of pyroglutamylglutamyl-
prolineamide, a peptide related to thyrotrophin-releasing hormone, on rat
anterior pituitary cells in culture. J Endocrinol. 142:111–118.
30. Neri G, Malendovicz LK, Andreis P, Nussdorfer GG. 1993 Thyrotropin-
releasing hormone inhibits glucocorticoid secretion of rat adrenal cortex: in
vivo and in vitro studies. Endocrinology. 133:511–514.
31. Mabrouk MM, Bennett GW. 1993 Evaluation of the behavioural effects of a
novel thyrotrophin-releasing hormone (TRH)-like peptide (pGlu-Glu-ProH2,
EEP) in the rat. Br J Pharmacol. 110:178P (Abstract).
32. Harvey S, Trudeau VL, Ashworth RJ, Cockle SM. 1993 pGlutamylglutamylpro-
lineamide modulation of growth hormone secretion in domestic fowl: antagonism
of thyrotropin-releasing hormone action? J Endocrinol. 138:137–147.
33. Perlman JF, Nussenzveig DR, Osman R, Gershengorn MC. 1992 Thyrotropin-
releasing hormone binding to the mouse pituitary receptor does not involve
ionic interactions. A model for neutral peptide binding to G protein-coupled
receptors. J Biol Chem. 267:24413–24417.
34. Rondeel JMM, Klootwijk W, Linkels E, de Greef WJ, Visser TJ. 1994 Neu-
ral differentiation of the human neuroblastoma cell line IMR32 induces pro-
duction of a thyrotropin-releasing hormone-like peptide. Brain Res.
655:262–268.
35. Cummins PM, O’Connor B. 1996 Bovine brain pyroglutamyl aminopeptidase
(type-1): purification and characterisation of a neuropeptide-inactivating pep-
tidase. Int J Biochem Cell Biol. 28:883–893.
36. Schauder B, Schomburg L, Ko¨hrle J, Bauer K. 1994 Cloning of a cDNA
encoding an ectoenzyme that degrades thyrotropin-releasing hormone. Proc
Natl Acad Sci USA. 91:9534–9538.
37. Visser TJ, Klootwijk W. 1981 Approaches to a markedly increased sensitivity
of the radioimmunoassay for thyrotropin-releasing hormone by derivatiza-
tion. Biochim Biophys Acta. 673:454–466.
38. Suhonen-Malm A-S. 1987 Thyrotropin-releasing hormone immunoreactivity
in human blood, urine, spinal fluid, amniotic fluid, saliva, and gastric juice.
Acta Endocrinol (Copenh). 114:552–558.
39. Bertram C, Cockle SM. 1995 Detection of a novel peptide in blood from
patients with benign prostatic hyperplasia; a new test for prostatic disease? J
Endocrinol. [Suppl]147 (Abstract O53).
40. Minami H, Daniel H, Morse EL, Adibi SA. 1992 Oligopeptides: mechanism
of renal clearance depends on molecular structure. Am J Physiol.
263:F109–F115.
41. Zavaroni I, Deferrari G, Lugari R, et al. 1987 Renal metabolism of C-peptide
in man. J Clin Endocrinol Metab. 85:494–498.
42. Klootwijk W, de Boer RDH, Sleddens-Linkels E, et al. 1997 Urinary excretion
of the TRH-like peptide pyroglutamyl-glutamyl-prolineamide in rats. J En-
docrinol. 153:411–421.
43. Gkonos PJ, Kwok CK, Block NL, Roos BA. 1993 Expression of prostatic
TRH-like peptides differ between species and between malignant and non-
malignant tissues. Prostate. 23:135–147.
44. Nilsson O. 1996 Gastrointestinal carcinoids - aspects of diagnosis and classi-
fication. APMIS. 104:481–492.
,EEP-NH2 IN URINE 3073
 at Medical Library Erasmus MC on December 13, 2006 jcem.endojournals.orgDownloaded from 
